ARCA biopharma (ABIO) executive Ozeroff received 27,500 Stock Option (right to buy)

Insider transactions reported

Christopher David Ozeroff (executive at ARCA biopharma Inc., ABIO) reported that they received 27,500 Stock Option (right to buy) on Dec 14, 2021.

Reporting person

Ozeroff Christopher David

Options and other derivatives

Holdings before and after

• Stock Option (right to buy): 0 to 27,500 direct

Other positions listed

• Common Stock: 50,970 direct

Footnotes from the filing

1. 1. Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan (the Plan), vesting in 36 equal monthly installments from the date of grant, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan prior to such time. In the event of a change in control of the Issuer, 50% of the unvested options shall become fully and immediately vested upon the closing date of such change in control, provided, however, that on the earlier of (i) the one-year anniversary of the closing date or (ii) involuntary termination, any options that remain unvested on such earlier date shall become fully and immediately vested.

Transaction codes in this filing

Grant or award:

Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.

FAQ